{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:19:57Z","timestamp":1783171197503,"version":"3.54.6"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017520","name":"Chengdu Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016350","name":"Sichuan Provincial Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["25MSZX239"],"award-info":[{"award-number":["25MSZX239"]}],"id":[{"id":"10.13039\/501100016350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bbrc.2026.153971","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T22:13:53Z","timestamp":1778969633000},"page":"153971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PYCR2 contributes to sunitinib resistance in hepatocellular carcinoma by activating the PPAR signaling pathway"],"prefix":"10.1016","volume":"823","author":[{"given":"Xin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153971_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2026.153971_bib2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.153971_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbrc.2026.153971_bib4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41417-024-00764-w","article-title":"Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications","volume":"31","author":"Safri","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bbrc.2026.153971_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11901-020-00553-7","article-title":"Genomic landscape of HCC","volume":"19","author":"Nia","year":"2020","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.bbrc.2026.153971_bib6","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2026.153971_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1432423","article-title":"Targeted therapies in hepatocellular carcinoma: past, present, and future","volume":"14","author":"Gujarathi","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.153971_bib8","article-title":"Upregulation of miR-3130-5p enhances hepatocellular carcinoma growth by suppressing ferredoxin 1 : miR-3130-5p enhances HCC growth via inhibiting FDX1","volume":"17","author":"Xu","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153971_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/0113892029273682240111052317","article-title":"Analysis of the expression of PRDX6 in patients with hepatocellular carcinoma and its effect on the phenotype of hepatocellular carcinoma cells","volume":"25","author":"Mu","year":"2024","journal-title":"Curr. Genom."},{"key":"10.1016\/j.bbrc.2026.153971_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/0113892029308243240709073945","article-title":"Integrative bioinformatics analysis for targeting hub genes in hepatocellular carcinoma treatment","volume":"26","author":"Gudivada","year":"2025","journal-title":"Curr. Genom."},{"key":"10.1016\/j.bbrc.2026.153971_bib11","article-title":"Targeting metabolic reprogramming in hepatocellular carcinoma to overcome therapeutic resistance: a comprehensive review","volume":"170","author":"Wang","year":"2024","journal-title":"Biomed. & Pharmacother. = Biomed. & Pharmacother."},{"key":"10.1016\/j.bbrc.2026.153971_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.833396","article-title":"Differential degradation of TRA2A and PYCR2 mediated by ubiquitin E3 ligase E4B","volume":"10","author":"Lu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbrc.2026.153971_bib13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1078-0432.CCR-17-1707","article-title":"Global metabolic profiling identifies a pivotal role of proline and hydroxyproline metabolism in supporting hypoxic response in hepatocellular carcinoma","volume":"24","author":"Tang","year":"2018","journal-title":"Clin. Cancer Res. : Off. J. Amer. Assoc. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.153971_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","article-title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma","volume":"179","author":"Gao","year":"2019","journal-title":"CELL"},{"key":"10.1016\/j.bbrc.2026.153971_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bbrc.2023.09.007","article-title":"PYCR2 promotes growth and aerobic glycolysis in human liver cancer by regulating the AKT signaling pathway","volume":"680","author":"Wang","year":"2023","journal-title":"Biochem. Bioph. Res. Co."},{"key":"10.1016\/j.bbrc.2026.153971_bib16","doi-asserted-by":"crossref","DOI":"10.2174\/0118761429310703240823045808","article-title":"Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation","volume":"17","author":"Sensi","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153971_bib17","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.3748\/wjg.v28.i28.3573","article-title":"Combination approaches in hepatocellular carcinoma: how systemic treatment can benefit candidates to locoregional modalities","volume":"28","author":"da Fonseca","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2026.153971_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC)","volume":"14","author":"Chakraborty","year":"2022","journal-title":"CANCERS"},{"key":"10.1016\/j.bbrc.2026.153971_bib19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2026.153971_bib20","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2010.11.011","article-title":"Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma","volume":"54","author":"Marijon","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.153971_bib21","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2008.20.9908","article-title":"Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study","volume":"27","author":"Zhu","year":"2009","journal-title":"J. Clin. Oncol. : Off. J. Amer. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.153971_bib22","article-title":"BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors","volume":"10","author":"Liu","year":"2023","journal-title":"J. Big Data-Ger."},{"key":"10.1016\/j.bbrc.2026.153971_bib23","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"10.1016\/j.bbrc.2026.153971_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2016.07.044","article-title":"Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model","volume":"66","author":"Li","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2026.153971_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.31083\/j.fbl2902052","article-title":"Drug resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"29","author":"Lei","year":"2024","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.bbrc.2026.153971_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-024-01527-8","article-title":"Metabolic reprogramming in the tumor microenvironment of liver cancer","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.153971_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111763","article-title":"P5C as an interface of proline interconvertible amino acids and its role in regulation of cell survival and apoptosis","volume":"22","author":"Chalecka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153971_bib28","article-title":"Deciphering the effects of the PYCR family on cell function, prognostic value, immune infiltration in ccRCC and pan-cancer","volume":"25","author":"Chen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153971_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41420-020-00341-8","article-title":"The Janus-like role of proline metabolism in cancer","volume":"6","author":"Burke","year":"2020","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbrc.2026.153971_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108852","article-title":"Disease variants of human \u0394(1)-pyrroline-5-carboxylate reductase 2 (PYCR2)","volume":"703","author":"Patel","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbrc.2026.153971_bib31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hep.22698","article-title":"Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis","volume":"49","author":"Midorikawa","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2026.153971_bib32","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.3748\/wjg.v23.i44.7818","article-title":"Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data","volume":"23","author":"Yu","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2026.153971_bib33","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","article-title":"Drug resistance in cancer: mechanisms and tackling strategies","volume":"72","author":"Haider","year":"2020","journal-title":"Pharmacol. Rep. : PR"},{"key":"10.1016\/j.bbrc.2026.153971_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Sign. Transduct. Tar."},{"key":"10.1016\/j.bbrc.2026.153971_bib35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.9.1.143","article-title":"Early development of sunitinib in hepatocellular carcinoma","volume":"9","author":"Zhu","year":"2009","journal-title":"Expert Rev. Anticanc."},{"key":"10.1016\/j.bbrc.2026.153971_bib36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s13277-014-2608-3","article-title":"Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study","volume":"36","author":"Chen","year":"2015","journal-title":"Tumour Biol. : J. Int. Soc. Oncodevelopm. Biol. Med."},{"key":"10.1016\/j.bbrc.2026.153971_bib37","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1080\/15384047.2018.1470731","article-title":"The prognostic correlation between CD105 expression level in tumor tissue and peripheral blood and sunitinib administration in advanced hepatocellular carcinoma","volume":"19","author":"Yang","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbrc.2026.153971_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23333","article-title":"Sunitinib suppresses M2 polarization of macrophages in tumor microenvironment to regulate hepatocellular carcinoma progression","volume":"37","author":"Kong","year":"2023","journal-title":"J. Biochem. Mol. Toxic"},{"key":"10.1016\/j.bbrc.2026.153971_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166097","article-title":"PPARs in liver physiology","volume":"1867","author":"Berthier","year":"2021","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.bbrc.2026.153971_bib40","article-title":"Peroxisome proliferator-activated receptors as therapeutic target for cancer","volume":"28","author":"Wang","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bbrc.2026.153971_bib41","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1038\/s41598-024-55086-6","article-title":"Development of a promising PPAR signaling pathway-related prognostic prediction model for hepatocellular carcinoma","volume":"14","author":"Shi","year":"2024","journal-title":"Sci. Rep.-UK"},{"key":"10.1016\/j.bbrc.2026.153971_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165723","article-title":"PPARs and angiogenesis-implications in pathology","volume":"21","author":"Wagner","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153971_bib43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol. Cancer"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26007357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26007357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:46:42Z","timestamp":1783169202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26007357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"alternative-id":["S0006291X26007357"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153971","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PYCR2 contributes to sunitinib resistance in hepatocellular carcinoma by activating the PPAR signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153971"}}